Regeneron Pharmaceuticals Adjustments to Reconcile Net Income to Operating Cash Flow increased by 7.9% to $351.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 48.8%, from $236.40M to $351.70M.
t_adjustments_to_reconcile_net_income| Q2 '21 | Q1 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$2.47B | $1.13B | $522.80M | $549.80M | $54.00M | $106.50M | $790.50M | -$1.08B | -$49.40M | $345.10M | $236.40M | -$247.20M | $158.70M | $326.10M | $351.70M |
| QoQ Change | — | +145.6% | -53.7% | +5.2% | -90.2% | +97.2% | +642.3% | -236.4% | +95.4% | +798.6% | -31.5% | -204.6% | +164.2% | +105.5% | +7.9% |
| YoY Change | — | — | — | -51.3% | — | — | +43.8% | <-999% | -146.4% | — | -70.1% | +77.1% | +421.3% | -5.5% | +48.8% |